Citius Pharmaceuticals (CTXR) Operating Expenses (2010 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Operating Expenses came in at $33.5 million in Q1 2026, up 197.79% YoY from $11.3 million in Q1 2025, and up 175.45% on a QoQ basis from $12.2 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Operating Expenses (2010 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 17 years of Operating Expenses data on file, last reported at $33.5 million in Q1 2026.
- Quarterly Operating Expenses rose 197.79% year-over-year to $33.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62.9 million (up 46.41% YoY) and the FY2025 annual result came in at $38.5 million, down 8.26% from the prior year.
- Operating Expenses climbed to $33.5 million in Q1 2026, from $12.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $33.5 million in Q1 2026 to a low of $7.2 million in Q4 2022.
- A 5-year average of $11.0 million and a median of $10.0 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2025 — Operating Expenses decreased 23.65% — and 2026, when it surged 197.79%.
- Tracing CTXR's Operating Expenses over 5 years: stood at $7.2 million in 2022, then advanced by 28.84% to $9.3 million in 2023, then increased by 7.48% to $10.0 million in 2024, then increased by 21.26% to $12.2 million in 2025, then soared by 175.45% to $33.5 million in 2026.
- The last three Operating Expenses figures came in at $33.5 million (Q1 2026), $12.2 million (Q4 2025), and $8.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Citius Pharmaceuticals | 15.60 Mn | 15.60 Mn | 1.00 Mn | 12.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.53 Mn |
| Dec 31, 2025 | 12.17 Mn |
| Sep 30, 2025 | 8.44 Mn |
| Jun 30, 2025 | 8.79 Mn |
| Mar 31, 2025 | 11.26 Mn |
| Dec 31, 2024 | 10.04 Mn |
| Sep 30, 2024 | 11.05 Mn |
| Jun 30, 2024 | 10.63 Mn |
| Mar 31, 2024 | 10.97 Mn |
| Dec 31, 2023 | 9.34 Mn |
| Sep 30, 2023 | 10.12 Mn |
| Jun 30, 2023 | 8.67 Mn |
| Mar 31, 2023 | 10.69 Mn |
| Dec 31, 2022 | 7.25 Mn |
| Sep 30, 2022 | 7.55 Mn |
| Jun 30, 2022 | 8.92 Mn |
| Mar 31, 2022 | 7.59 Mn |
| Dec 31, 2021 | 9.26 Mn |
| Sep 30, 2021 | 5.20 Mn |
| Jun 30, 2021 | 5.98 Mn |